Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Probiotics for mental health? A new review finds promising signals and major gaps

28

Aug 2026

Probiotics for mental health? A new review finds promising signals and major gaps

This narrative review examines how psychobiotics may influence anxiety, depression, bipolar disorder, and schizophrenia through gut-brain pathways involving neurotransmitters, inflammation, immune regulation, gut barrier function, and stress signaling. Specific Lactobacillus and Bifidobacterium strains showed encouraging effects, but wide differences in strains, doses, populations, and study designs currently limit clinical translation.

Blood-brain barrier-crossing blood pressure drugs linked to lower dementia risk

27

Aug 2026

Blood-brain barrier-crossing blood pressure drugs linked to lower dementia risk

In a large Australian cohort of adults with hypertension, use of blood-brain barrier-crossing antihypertensive medications was associated with a lower risk of dementia and mortality than use of non-crossing drugs. The association was strongest for beta-blockers and angiotensin II receptor blockers, although the observational design means the findings cannot establish causality.

The US switch in shingles vaccines revealed an unexpected heart health pattern

27

Aug 2026

The US switch in shingles vaccines revealed an unexpected heart health pattern

In a natural experiment involving 72,920 propensity-matched US adults aged 60 years and older, recombinant shingles vaccination was associated with a 9% lower cardiovascular disease burden over seven years compared with the live attenuated vaccine. Lower burdens of ischemic heart disease and heart failure were seen in both sexes, while ischemic stroke was significantly lower only among men, supporting further clinical trials and mechanistic studies

$15 million trial aims to improve treatment decisions for older AML patients

27

Aug 2026

$15 million trial aims to improve treatment decisions for older AML patients

A newly funded national clinical trial initiative will gather critical evidence to determine the best treatment strategies for older adults with acute myeloid leukemia (AML), an aggressive, fast-moving blood cancer that leaves a substantial proportion of older patients facing uncertainty about whether to proceed to stem cell transplantation or continue non-transplant therapy.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Mercury Pharmaceuticals
Mercury Pharmaceuticals

Why Us?

KNOWLEDGE OF RESEARCH ENVIRONMENT

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.

UNDERSTANDING INDUSTRIAL NEEDS

Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.

FOCUSED PROJECT MANAGEMENT

Smart approach to project management that helps speed up development stages and decision making.

INVESTMENT CAPABILITY

Availability of own investment up to 2m€ per project allows us to reach the next value milestone.